Acer Inc, the nation's second largest laptop vendor, yesterday vowed to regain its one-time glory as No. 1 in its home market by the end of this year, through an enhanced marketing strategy and closer cooperation with its distribution and sales channels.
"Our laptop shipments to the local market soared by 80 percent from a year ago to over 10,000 units in March alone," Scott Lin (
"We are confident of regaining the No. 1 spot in the market this year ... with a sales target of around 200,000 notebooks in Taiwan," Lin said.
PHOTO: CHO YI-CHUN, TAIPEI TIMES
To accomplish the goal, the company plans to pour more money into marketing to further build up its brand identity.
It will also strengthen its alliance with non-information technology sales channels like FNAC and Carrefour by giving them more exclusive products as well as profit rebates, the executive added.
Asustek Computer (華碩) led Taiwan's laptop market with a 29.4 percent market share in the fourth quarter of last year, followed by Acer's 23.8 percent, Hewlett-Packard Taiwan's 14.1 percent, IBM Taiwan Corp's 12 percent and Toshiba Corp's 3.8 percent, according to figures from International Data Corp (IDC).
Acer yesterday rolled out its new model, TravelMate 3000, equipped with a 12.1-inch-wide screen and Intel Corp's latest Sonoma platform, the upgraded Centrino mobile technology, using the 1.73 GHz central processing unit, with a price tag of NT$49,900 per unit.
The company hopes to sell 5,000 units per month and win a 40 percent market share in the 12-inch laptop segment after spending NT$40 million to NT$50 million on marketing this year, Lin said.
The 12-inch laptop segment accounted for 27 percent of some 590,000 notebook shipments last year, up from a share of merely 12 percent in 2003, IDC analyst Sunny Chen (
Just a few years ago, the millennial generation — generally defined as those born from the early 1980s through the mid-1990s — was synonymous with youthful rebellion. However, now, as the millennials ease into early middle age, they are finding their path out of their parents’ basement to be a lot harder than it was for earlier generations. The fundamental problem is that millennials are not building wealth. The wealth of the median US household headed by someone 35 or younger has actually shrunk in inflation-adjusted terms since the mid-2000s, even as the wealth of older Americans has continued to grow. An
‘LITTLE CHOICE’: The airline said it expected only about 8,000 of its 29,000 employees to be working by next month, but hoped to have 21,000 in the next two years Qantas Airways Ltd plans to cut at least 6,000 jobs and keep 15,000 more workers on extended furloughs as Australia’s largest airline tries to survive the coronavirus pandemic. Qantas yesterday announced a plan to reduce costs by billions of dollars and raise fresh capital. The plan includes grounding 100 planes for a year or more and immediately retiring its six remaining Boeing Co 747 planes. Chief executive Alan Joyce said the airline has to become smaller as it braces for several years of much lower revenues. He said the furloughed workers faced a long interruption to their airline careers. “The actions that we’re taking
Apple Inc’s decision to stop using Intel Corp processors in its Mac computers and switching to its own chips might benefit Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) and boost Taiwan’s high-tech exports, Australia and New Zealand Banking Group (ANZ) said in a note on Tuesday. The US tech giant announced the “Apple silicon” initiative at its annual Worldwide Developers’ Conference, which started on Monday. The company said the first Mac powered by its own chips would debut by the end of this year and all product lines might shift to the new architecture in the next two years. TSMC is likely to
EXPERIMENTAL DRUG: While news about a COVID-19 vaccine is more eye-catching, developing a treatment would be more viable, the Senhwa boss said Senhwa Biosciences Inc (生華科) aims to raise NT$1.5 billion (US$50.57 million) by issuing 15 million new common shares in the third quarter of this year to fund the research of new drugs, including the experimental drug Silmitasertib for the treatment of COVID-19, the company said on Monday. That would be the firm’s largest fundraising effort after it raised more than NT$1.4 billion from an initial public offering on the Taipei Exchange (TPEX) in April 2017, chief financial officer Sarah Chang (張小萍) told the Taipei Times by telephone. The price of the new shares would depend on the firm’s average share price